PLX-4720

Name: PLX-4720
Brand: Selleck Chemicals
SKU: S1152
Rating: 5 (137 reviews)

For research use only.

Catalog No.S1152

137 publications

CAS No. 918505-84-7

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Selleck's PLX-4720 has been cited by 137 publications

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Nature, 2017, 548(7667):343-346

PubMed: 28792927 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Nature, 2015, 517(7536):583-8

PubMed: 25494202 ( click the link to review the publication )

Cell, 2015, 160(1-2):161-76

PubMed: 25594179 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2014, 4(7):816-27

PubMed: 24771846 ( click the link to review the publication )

Nature, 2013, 6;498(7452):109-12.

PubMed: 23685455 ( click the link to review the publication )

Cell, 2013, 29;154(5):1036-1046.

PubMed: 23993095 ( click the link to review the publication )

Nat Biotechnol, 2013, 31(7):630-7

PubMed: 23811600 ( click the link to review the publication )

Cancer Discov, 2013, 3(3):350-62

PubMed: 23288408 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Sci Adv, 2020, 6(9):eaax3223

PubMed: 32133394 ( click the link to review the publication )

Genomics Proteomics Bioinformatics, 2020, 12 pii: S1672-0229(20)30052-8

PubMed: 32413516 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):191

PubMed: 32913191 ( click the link to review the publication )

Cancer Discov, 2020, 4;CD-20-0329

PubMed: 32499221 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2020, S0925-4439(20)30409-9

PubMed: 33385518 ( click the link to review the publication )

J Transl Med, 2020, 11;18(1):192

PubMed: 32393282 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Transl Oncol, 2020, 13(2):355-364

PubMed: 31887630 ( click the link to review the publication )
Cell Rep, 2020, 30(2):510-524

PubMed: 31940493 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, S1097-2765(19)30838-X

PubMed: 31836388 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5232

PubMed: 31745079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5167

PubMed: 31727888 ( click the link to review the publication )

Cell Syst, 2019, 9(4):366-374

PubMed: 31521607 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Thyroid, 2019, 29(1):79-92

PubMed: 30398411 ( click the link to review the publication )

Oncogene, 2019, 38(22):4384-4396

PubMed: 30710146 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(12):2506-2516

PubMed: 31229500 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31083627 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):480-494

PubMed: 30582770 ( click the link to review the publication )

Mol Cell Proteomics, 2019, 18(6):1096-1109

PubMed: 30890564 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7779

PubMed: 31123282 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):932-950

PubMed: 31096110 ( click the link to review the publication )

Biomol Ther (Seoul), 2019, 27(3):302-310

PubMed: 30293252 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(7):1426-1435

PubMed: 31063355 ( click the link to review the publication )

Genes Genomics, 2019, 41(11):1273-1280

PubMed: 31388978 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1482

PubMed: 29662054 ( click the link to review the publication )

Genome Res, 2018, 28(9):1353-1363

PubMed: 30061114 ( click the link to review the publication )

J Control Release, 2018, 277:48-56

PubMed: 29550398 ( click the link to review the publication )
Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10902

PubMed: 30026510 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Med Sci (Basel), 2018, 6(1)

PubMed: 29304009 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Biophys J, 2018, 114(6):1499-1511

PubMed: 29590606 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(14):3953-3965

PubMed: 28096271 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2161-2172

PubMed: 28242615 ( click the link to review the publication )

Oncogene, 2017, 36(32):4585-4596

PubMed: 28368422 ( click the link to review the publication )

Br J Cancer, 2017, 116(8):1065-1076

PubMed: 28301874 ( click the link to review the publication )

Mol Oncol, 2017,

PubMed: 28182330 ( click the link to review the publication )

Neoplasia, 2017, 19(11):932-940

PubMed: 28963969 ( click the link to review the publication )

Sci Rep, 2017, 7:44123

PubMed: 28276530 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2017, 154:350-356

PubMed: 28365424 ( click the link to review the publication )

Am J Physiol, Cell Physiol, 2017,

PubMed: 28100485 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(4):947-959

PubMed: 28052651 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(2):219-237

PubMed: 27974353 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115140-115152

PubMed: 29383148 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2016,

PubMed: 26787892 ( click the link to review the publication )

Cell Rep, 2016, 10.1016/j.celrep.2016.05.064

PubMed: 27320919 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )
Oncogene, 2016, 35(20):2675-80

PubMed: 26119932 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(20):2612-25

PubMed: 27503857 ( click the link to review the publication )

Pharm Biol, 2016, 54(4):732-9

PubMed: 26931349 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2876-2888

PubMed: 27571413 ( click the link to review the publication )

Oncotarget, 2016, 7(50):81995-82012

PubMed: 27835901 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Nat Struct Mol Biol, 2015, 22(1):37-43

PubMed: 25437913 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1652-64

PubMed: 25617424 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(6):E536-45

PubMed: 25624498 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4573-81

PubMed: 26363009 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Med Chem, 2015, 58(4):1818-31

PubMed: 25611072 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 10.1111/pcmr.12364

PubMed: 25728708 ( click the link to review the publication )

Front Oncol, 2015, 10.3389/fonc.2015.00095

PubMed: ( click the link to review the publication )

Front Oncol, 2015, 5:95

PubMed: 26029660 ( click the link to review the publication )

J Cell Physiol, 2015, 10.1002/jcp.24888

PubMed: 25600161 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Exp Cell Res, 2015, 1;338(2):127-35

PubMed: 26384551 ( click the link to review the publication )

Biomol Ther (Seoul), 2015, 23(4):320-6

PubMed: 26157547 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26172302 ( click the link to review the publication )
Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(9):2410-23

PubMed: 24573550 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7079-89

PubMed: 25320010 ( click the link to review the publication )

Cancer Res, 2014, 74(15):4122-32

PubMed: 25035390 ( click the link to review the publication )

Mol Syst Biol, 2014, 10:772

PubMed: 25538140 ( click the link to review the publication )

Cell Rep, 2014, 10.1016/j.celrep.2014.10.024

PubMed: ( click the link to review the publication )

Cell Rep, 2014, 9(4):1375-86

PubMed: 25456132 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(9):1314-23

PubMed: 25061102 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(5):2598-608

PubMed: 24550330 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Toxicol Lett, 2014, 10.1111/cmi.12305

PubMed: 24779413 ( click the link to review the publication )

J Pharm Pharm Sci, 2014, 17(1):154-68

PubMed: 24735766 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87457

PubMed: 24475291 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101286

PubMed: 24983357 ( click the link to review the publication )

Oncotarget, 2014, 5(22):11237-51

PubMed: 25365078 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(16):4383-91

PubMed: 23812671 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 27(1):124-33

PubMed: 24112705 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1171-9

PubMed: 23615632 ( click the link to review the publication )

Oncogenesis, 2013, 2:e44

PubMed: 23588493 ( click the link to review the publication )

Clin Endocrinol, 2013, 81(1):109-16

PubMed: 24382015 ( click the link to review the publication )

Transl Oncol, 2013, 6(4):470-81

PubMed: 23908690 ( click the link to review the publication )

Mol Cell Biochem, 2013, 372(1-2):65-74

PubMed: 22941213 ( click the link to review the publication )
J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 925:124-8

PubMed: 23537694 ( click the link to review the publication )

J Biomol Screen, 2013, 19(4):526-37

PubMed: 24361645 ( click the link to review the publication )

J Membr Biol, 2013, 247(2):137-45

PubMed: 24258620 ( click the link to review the publication )

Sci Signal, 2013, 6(281):ra51

PubMed: 23800469 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1530-41

PubMed: 24152792 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(12):3316-27

PubMed: 22553342 ( click the link to review the publication )

Genes Dev, 2012, 26(10):1055-69

PubMed: 22549727 ( click the link to review the publication )

Oncogene, 2012, 32(40):4836-44

PubMed: 23208503 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(11):2652-60

PubMed: 22718120 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Biol Chem, 2012, 287(1):91-104

PubMed: 22027819 ( click the link to review the publication )

Biochem J, 2012, 450(2):285-94

PubMed: 23234544 ( click the link to review the publication )

Oncotarget, 2012, 3(12):1688-99

PubMed: 23518796 ( click the link to review the publication )

Mol Biol Cell, 2011, 22(23):4647-56

PubMed: 21976697 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23235

PubMed: 21829721 ( click the link to review the publication )

PLoS One, 2011, 6(11):e26908

PubMed: 22125603 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Targets

C-Raf-1 (Y340D/Y341D) ^[1] (Cell-free assay)	B-Raf (V600E) ^[1] (Cell-free assay)	BRK ^[1] (Cell-free assay)	B-Raf ^[1] (Cell-free assay)
6.7 nM	13 nM	130 nM	160 nM

In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-Raf^V600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-Raf^V600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-Raf^V600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. ^[1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN⁺ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN^- cells to PLX-4720-induced apoptosis. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
DU-4475	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMEe0OVch\|ryP	MknVV2FPT0WU
EoL-1-cell	NWXZXGttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nJXmlEPTB;MD6xOFE3PiEQvF2=	MlS4V2FPT0WU
C32	NIDtb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmqwTWM2OD1yLkG1NVMyKM7:TR?=	MlHiV2FPT0WU
M14	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMkG3OVch\|ryP	NUK3SW5GW0GQR1XS
CP50-MEL-B	NI\sXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzy[npKSzVyPUCuNlk4QDRizszN	MkDWV2FPT0WU
A101D	NWD4SWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1ewdmlEPTB;MD6zNlU5QSEQvF2=	MmniV2FPT0WU
G-361	NWnoS\|lKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwM{S2N\|ch\|ryP	MVfTRW5ITVJ?
HT-144	M2jhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPLfmVKSzVyPUCuN\|Y{OjlizszN	M1TFNXNCVkeHUh?=
ACN	M3nNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnf4TWM2OD1yLkO4OFc4KM7:TR?=	MmmxV2FPT0WU
COLO-829	NF62e2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYO0SZVmUUN3ME2wMlM5QTZ6IN88US=>	MWTTRW5ITVJ?
MEL-HO	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzCTWM2OD1yLkSxNVc6KM7:TR?=	Mm\LV2FPT0WU
SH-4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\ySlRKSzVyPUCuOFE1OjJizszN	NGT3PXNUSU6JRWK=
SK-MEL-3	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnrN\|NKSzVyPUCuOVE2PjhizszN	MV3TRW5ITVJ?
A375	MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLydFlKSzVyPUCuOlc{PTlizszN	NWrGOJFtW0GQR1XS
MMAC-SF	M1HZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfF[I5WUUN3ME2wMlY5PjF2IN88US=>	MWPTRW5ITVJ?
BHT-101	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnh[3VOUUN3ME2wMlcxPzB{IN88US=>	MlfiV2FPT0WU
K5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUe0b4RYUUN3ME2wMlc3OTR6IN88US=>	MWfTRW5ITVJ?
BV-173	NFfzc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorWTWM2OD1yLke5OlQ1KM7:TR?=	M4PwRXNCVkeHUh?=
RVH-421	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPwcXZKSzVyPUCuPFY4QTZizszN	MmnlV2FPT0WU
HCC2218	NEHnS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;2fWlEPTB;MD64O\|g1PCEQvF2=	MnvBV2FPT0WU
WM-115	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTESHdyUUN3ME2wMlg5Pjl{IN88US=>	MknIV2FPT0WU
SK-MEL-28	NVfvWoxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfUTWM2OD1zLkC0OVY6KM7:TR?=	NEW0TINUSU6JRWK=
COLO-679	M1;WPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO2dox7UUN3ME2xMlExPDZ2IN88US=>	NWDYV3U3W0GQR1XS
MZ7-mel	NFzD[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXNR2R3UUN3ME2xMlE1QTZ\|IN88US=>	M2j0WHNCVkeHUh?=
SK-MEL-30	NW[2UZljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrLbWFKSzVyPUGuN\|M{QDZizszN	NX\TTo1XW0GQR1XS
NCI-H209	NYPLTmhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTFwNkC4OkDPxE1?	MnuyV2FPT0WU
HTC-C3	NXvy[4hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;iVJBIUUN3ME2xMlY3Ojl2IN88US=>	NHnITnBUSU6JRWK=
KARPAS-45	NX\jfW9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPNTWM2OD1{LkC0PVc5KM7:TR?=	MmLZV2FPT0WU
NCI-SNU-5	NWjZNYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XiUmlEPTB;Mj6xNVk3QSEQvF2=	MYHTRW5ITVJ?
KP-4	M2PQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrwfIhKSzVyPUKuN\|A4QDdizszN	M3rGcXNCVkeHUh?=
PA-1	NW\QbHNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrjRWdKSzVyPUKuO\|I3PzNizszN	NHLnXXlUSU6JRWK=
HuO-3N1	M33TPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHG5UmxKSzVyPUKuPFc6PDZizszN	MnT3V2FPT0WU
NCI-H358	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrwWmpKSzVyPUKuPVIzOzJizszN	NY\kNZl{W0GQR1XS
CTB-1	MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo[wTWM2OD1\|LkSwNVc3KM7:TR?=	MofvV2FPT0WU
697	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HXdWlEPTB;Mz61OVI3PiEQvF2=	M2DU[3NCVkeHUh?=
CP66-MEL	NH;Gb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjR[XhKSzVyPUSuNVU6OjdizszN	M1jvfXNCVkeHUh?=
NB13	NFz5OlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTRwNEmxO\|kh\|ryP	M1LEcXNCVkeHUh?=
DBTRG-05MG	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTRwNUOzNlUh\|ryP	MUHTRW5ITVJ?
A2058	M2XaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTRwN{KxOlQh\|ryP	MkfaV2FPT0WU
KG-1	NGjJcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O3eWlEPTB;ND63N\|kxQCEQvF2=	NIr1TJpUSU6JRWK=
8305C	M1;zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILKUlhKSzVyPUWuNVg4OyEQvF2=	MknhV2FPT0WU
RPMI-7951	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPHTWM2OD13LkiwNlg{KM7:TR?=	Mlr5V2FPT0WU
CHL-1	NYjORVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{WyOWlEPTB;NT65O\|YxOyEQvF2=	MkLoV2FPT0WU
TI-73	M{PMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfNTWM2OD14LkCwPVAzKM7:TR?=	MVHTRW5ITVJ?
HT-1080	NHzEZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnTU\|M5UUN3ME22MlExQTR4IN88US=>	M4XRUXNCVkeHUh?=
ES5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHJTWM2OD14LkG0PVI1KM7:TR?=	NGDJcZlUSU6JRWK=
8-MG-BA	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTZwMUixNlkh\|ryP	MoPuV2FPT0WU
NB7	M{LaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVK1PFQxUUN3ME22MlIyOzd\|IN88US=>	MWPTRW5ITVJ?
H4	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PVOGlEPTB;Nj6yNlQ6OyEQvF2=	NVziW25NW0GQR1XS
CAL-72	NHzYcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnj0TWM2OD14LkS1OFI{KM7:TR?=	NW[xNXdWW0GQR1XS
HCC1806	NHvIdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjCNm8zUUN3ME22MlgyQTNzIN88US=>	NGXzT4tUSU6JRWK=
BCPAP	NF7Bb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTdwMkG3OlQh\|ryP	Mn3sV2FPT0WU
LB2241-RCC	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XLSGlEPTB;Nz6zOlkxPyEQvF2=	M4f3PXNCVkeHUh?=
COLO-741	NUPhbWhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf2TWM2OD16LkCxOlc6KM7:TR?=	MYPTRW5ITVJ?
HSC-3	NFTKZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fldWlEPTB;OD6wO\|A3QCEQvF2=	MYLTRW5ITVJ?
SW982	NFHQT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHHO2VKSzVyPUiuOFE2OTZizszN	NE\2eYhUSU6JRWK=
GCT	NVPqZoFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;VNnlKSzVyPUiuO\|U{OTRizszN	MY\TRW5ITVJ?
KY821	M3;COmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTlwMEWxO\|gh\|ryP	MUHTRW5ITVJ?
JVM-3	NF7ke4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTlwNU[5PVkh\|ryP	NVXGWVByW0GQR1XS
RS4-11	NHzaXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLBTWM2OD17Lk[wOFgh\|ryP	NIS5cJhUSU6JRWK=
VA-ES-BJ	NGHMNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTFyLkCxOFkh\|ryP	NYTPdHJQW0GQR1XS
A431	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHQTWM2OD1zMD60NlEzKM7:TR?=	MnHBV2FPT0WU
LXF-289	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH63[otKSzVyPUGwMlQ2QCEQvF2=	MWrTRW5ITVJ?
SK-MEL-24	NX\oXYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFOyUmNKSzVyPUGwMlgzPzRizszN	M4XicXNCVkeHUh?=
NOS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILEVIFKSzVyPUGwMlg1PzJizszN	NH7Je3dUSU6JRWK=
KNS-62	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLKTWM2OD1zMT6yOFA1KM7:TR?=	MVfTRW5ITVJ?
SK-HEP-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1yw[GlEPTB;MUGuN\|UzPyEQvF2=	MnK5V2FPT0WU
A3-KAW	MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v2TGlEPTB;MUGuO\|E4QCEQvF2=	Ml7VV2FPT0WU
SK-LU-1	NX[2[\|hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDaTohxUUN3ME2xNk4zPjV3IN88US=>	NXPETHc3W0GQR1XS
TYK-nu	NYT5dlRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXNTWM2OD1zMj6zPVMzKM7:TR?=	NXT3epVwW0GQR1XS
NMC-G1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTF{Lk[wOlIh\|ryP	MXXTRW5ITVJ?
BB65-RCC	NYfG[5ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWqyRW9uUUN3ME2xNk44OTZ7IN88US=>	MoHqV2FPT0WU
QIMR-WIL	NIjVPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fpPGlEPTB;MUKuPFg{OyEQvF2=	NYDGbpM5W0GQR1XS
D-566MG	NG\0Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrnWmJKSzVyPUGzMlk2PzZizszN	NEjEWpJUSU6JRWK=
KYSE-140	NHjGXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjYe5JjUUN3ME2xOE4xPzV\|IN88US=>	NHLDfJBUSU6JRWK=
SCC-4	Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkGxTWM2OD1zND6zN\|U6KM7:TR?=	NUDmT5hyW0GQR1XS
U251	NGfydpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTF2Lki0PVIh\|ryP	NYm1e2o5W0GQR1XS
D-542MG	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\wPWlEPTB;MUSuPVIzOiEQvF2=	NGj4NZdUSU6JRWK=
LAMA-84	NHu2bIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmf2TWM2OD1zND65PVMzKM7:TR?=	MXjTRW5ITVJ?
NCI-H720	NWXieY5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHDem5XUUN3ME2xOU4zPjh2IN88US=>	MlHRV2FPT0WU
DEL	NFvhTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTF3LkSyPVMh\|ryP	M{js[3NCVkeHUh?=
SBC-1	M4jtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jWeGlEPTB;MUWuOFMxPSEQvF2=	MYTTRW5ITVJ?
ECC10	Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrDW5VKSzVyPUG1MlQ1PThizszN	NIHsR2hUSU6JRWK=
Daoy	Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzGTWM2OD1zNT63OlE3KM7:TR?=	MkXuV2FPT0WU
SCH	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPJZlhKSzVyPUG1Mlc5OzVizszN	NYTkWYw{W0GQR1XS
MZ2-MEL	NXzOO4N6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTF4LkC2OFYh\|ryP	MUnTRW5ITVJ?
CAL-12T	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrFTWM2OD1zNj60PFYzKM7:TR?=	M2jaWXNCVkeHUh?=
KE-37	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\xR2lEPTB;MU[uPFExPyEQvF2=	Mnv0V2FPT0WU
LS-411N	NGrYV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jaSWlEPTB;MUeuNVE5KM7:TR?=	MYHTRW5ITVJ?
NCI-H2228	MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfQPW4{UUN3ME2xO{4{ODdzIN88US=>	MWnTRW5ITVJ?
SK-MEL-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTF5LkS5OlUh\|ryP	MnfIV2FPT0WU
HN	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjtcnhGUUN3ME2xO{44OjR6IN88US=>	MmfDV2FPT0WU
NCI-H1648	NGnGT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLyTWM2OD1zNz64NVgh\|ryP	MUXTRW5ITVJ?
IA-LM	M3ftUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jidmlEPTB;MUiuN\|E4OiEQvF2=	M3XxenNCVkeHUh?=
EW-13	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3UTHZKSzVyPUG4MlU4ODhizszN	MYXTRW5ITVJ?
YKG-1	M1TxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInZO\|ZKSzVyPUG5MlU4OTFizszN	MXTTRW5ITVJ?
KNS-81-FD	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHlTWM2OD1zOT61PFU5KM7:TR?=	MWnTRW5ITVJ?
23132-87	NYrSeJc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Lh[GlEPTB;MUmuO\|Y1OiEQvF2=	NVHVT5RzW0GQR1XS
NUGC-3	NG\LeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HnXWlEPTB;MUmuPVg5PyEQvF2=	MofkV2FPT0WU
5637	NILoOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rWcWlEPTB;MkCuNFQ4QCEQvF2=	NYDlTpZsW0GQR1XS
NCI-H1755	Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjlTWM2OD1{MD60O\|Y1KM7:TR?=	Mm\QV2FPT0WU
RH-18	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXzTWM2OD1{MD61O\|Q5KM7:TR?=	NIThTZlUSU6JRWK=
RXF393	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXKTWM2OD1{MD62O\|U3KM7:TR?=	MWXTRW5ITVJ?
LU-134-A	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrSSY1KSzVyPUKwMlcxPTZizszN	M4TBWXNCVkeHUh?=
TE-12	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTJyLkeyNFEh\|ryP	NY\6VoVuW0GQR1XS
MOLT-4	NV;yT2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TVTWlEPTB;MkGuNVkyPSEQvF2=	NGLNVHpUSU6JRWK=
IGR-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1WzNmlEPTB;MkGuN\|c6PiEQvF2=	MX\TRW5ITVJ?
HOP-92	MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTJzLkS5PFch\|ryP	NITnSY1USU6JRWK=
SK-MES-1	M2jIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXIWJhSUUN3ME2yNU44OzhzIN88US=>	MVjTRW5ITVJ?
LU-65	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXoTIVxUUN3ME2yNU45PjJ2IN88US=>	MXLTRW5ITVJ?
MS-1	NE\VdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTJ{LkGyNFMh\|ryP	NILqVXhUSU6JRWK=
LoVo	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJ{LkK0OEDPxE1?	M4jWT3NCVkeHUh?=
A704	NFTzOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3MO2ZwUUN3ME2yNk42OTV3IN88US=>	NFGzNpZUSU6JRWK=
HT-1376	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXiTWM2OD1{Mj62NFU6KM7:TR?=	NGPpfmVUSU6JRWK=
IST-MEL1	NYT6V49RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13oVGlEPTB;MkKuOlc2OSEQvF2=	NEjVe2NUSU6JRWK=
Ramos-2G6-4C10	NHHZVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTJ{LkezOlYh\|ryP	NVLvO4dsW0GQR1XS
T47D	MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmT3TWM2OD1{Mj63PVc6KM7:TR?=	NYOyTmN3W0GQR1XS
HT-1197	M2\EZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjaTWM2OD1{Mz6wPFE4KM7:TR?=	NVLUZm15W0GQR1XS
LB2518-MEL	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{G5T2lEPTB;MkOuOlQyOiEQvF2=	Mlv5V2FPT0WU
J-RT3-T3-5	M3L0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP4SGlKSzVyPUK0Mlc2QTVizszN	NUjhNYlGW0GQR1XS
SK-NEP-1	NGTLUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTJ2Lki3OFQh\|ryP	MXrTRW5ITVJ?
NCI-H526	M3j6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTJ3LkCwNlMh\|ryP	NICwS\|JUSU6JRWK=
IST-SL1	M17JT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTJ3LkK3OVEh\|ryP	MofuV2FPT0WU
HH	NEfYTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXUTWM2OD1{NT6zNVkzKM7:TR?=	MUjTRW5ITVJ?
NCI-H82	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPj[\|ZMUUN3ME2yOU46OzhizszN	M1;SNHNCVkeHUh?=
SNU-449	MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;iWWlEPTB;MkeuNlAyQCEQvF2=	NHL0SWJUSU6JRWK=
COR-L23	NVzFZZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLve\|ZKSzVyPUK3MlI5OTNizszN	NWr6NJRiW0GQR1XS
LOXIMVI	M2nEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXj3OnZUUUN3ME2yO{4{PjhizszN	MYHTRW5ITVJ?
GR-ST	NWLiZow5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnENWJwUUN3ME2yO{43PzB4IN88US=>	MUXTRW5ITVJ?
NCI-SNU-1	M4j0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonOTWM2OD1{Nz65OFQh\|ryP	MkjUV2FPT0WU
ALL-PO	NHnWdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG[5T29KSzVyPUK4MlE3ODRizszN	NEfTbVBUSU6JRWK=
ML-2	M{TtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLMN4VpUUN3ME2yPE4zQDF2IN88US=>	NX21No1HW0GQR1XS
HOP-62	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i5NWlEPTB;MkiuO\|E{KM7:TR?=	Mmj2V2FPT0WU
EGI-1	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfvelRKSzVyPUK4Mlg5PDVizszN	NVmwfXQxW0GQR1XS
TCCSUP	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUS3R3d3UUN3ME2yPE46Ojd{IN88US=>	M1POXHNCVkeHUh?=
LB996-RCC	MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH4TWM2OD1{OT61OlgzKM7:TR?=	NIDNN\|RUSU6JRWK=
LCLC-97TM1	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;5OGlEPTB;M{KuNVk3PCEQvF2=	MoLTV2FPT0WU
NCI-H1304	MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTITWM2OD1\|Mj6zN\|AyKM7:TR?=	MXnTRW5ITVJ?
KP-N-YS	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\0eWlEPTB;M{KuOVk4OyEQvF2=	NHG3Zm5USU6JRWK=
NCI-H1770	MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULzT2pbUUN3ME2zN{4yPjR6IN88US=>	M1jWTHNCVkeHUh?=
EM-2	M{HYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HrcmlEPTB;M{OuOlUxPCEQvF2=	MnPFV2FPT0WU
ChaGo-K-1	Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvLOnJPUUN3ME2zN{44OjN4IN88US=>	NFfTUmhUSU6JRWK=
ACHN	M3K4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLrTWM2OD1\|Mz64N\|g2KM7:TR?=	NHG1TZdUSU6JRWK=
MN-60	M4nqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLUTWM2OD1\|Mz64OVQ1KM7:TR?=	MVXTRW5ITVJ?
EW-18	NF[z[\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PyU2lEPTB;M{OuPFk4OSEQvF2=	NFfkSJFUSU6JRWK=
KGN	NVi0ZmV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTN3LkeyPVIh\|ryP	M3z2S3NCVkeHUh?=
U031	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXnToxKSzVyPUO1MlgyOzJizszN	MoLKV2FPT0WU
HMV-II	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTN4LkC3O\|Qh\|ryP	M{TWfHNCVkeHUh?=
L-363	NWPud4ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLFTWM2OD1\|Nz62OFU2KM7:TR?=	NIrobW9USU6JRWK=
NCI-H1155	Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[1N\|NKSzVyPUO4MlAxOTVizszN	MUTTRW5ITVJ?
NCI-H1793	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL2S\|BbUUN3ME2zPE4yODJ4IN88US=>	MXLTRW5ITVJ?
P30-OHK	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXMTWM2OD1\|OD6xN\|MzKM7:TR?=	NV\aOlh4W0GQR1XS
AN3-CA	NWTYTW55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTN6LkG2NVUh\|ryP	NI\DRolUSU6JRWK=
UACC-257	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjJUJc6UUN3ME2zPE44QSEQvF2=	NITCW2JUSU6JRWK=
MCF7	M325W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\WTWM2OD1\|OT64OlI6KM7:TR?=	MkjuV2FPT0WU
KP-N-YN	NFrBVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\YdmlEPTB;NECuOFI5PSEQvF2=	MnHNV2FPT0WU
T98G	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LvR2lEPTB;NECuOFk2PyEQvF2=	NF7zeFRUSU6JRWK=
HGC-27	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLSTWM2OD12Mz6yO\|Qh\|ryP	NUL5PW03W0GQR1XS
NCI-H1092	NHXCd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjOU2VXUUN3ME20N{4zQDl3IN88US=>	M4nORnNCVkeHUh?=
KARPAS-299	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVH6fGNoUUN3ME20N{4{ODdzIN88US=>	M{HWfnNCVkeHUh?=
LB1047-RCC	M4Sxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7ubnVKSzVyPUS0Mlk6PTlizszN	NFXOTVBUSU6JRWK=
786-0	NIDmU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXBT4hKSzVyPUS1MlY2KM7:TR?=	MXvTRW5ITVJ?
HCC2157	NYTwS401T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTR4LkCzOVkh\|ryP	NXfVNVdHW0GQR1XS
NY	NIq0VGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrzNVlKSzVyPUS2MlE4PzhizszN	NIrZZ5pUSU6JRWK=
EFM-19	M13ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zO[WlEPTB;NE[uO\|U{OyEQvF2=	NVPucohDW0GQR1XS
EW-16	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vWVmlEPTB;NE[uO\|gxPiEQvF2=	MonsV2FPT0WU
UM-UC-3	MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe1cJpYUUN3ME20Ok45ODV7IN88US=>	NV;TW\|NQW0GQR1XS
HT-29	NUfCZZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTR5Lki3PVIh\|ryP	NF\6PVBUSU6JRWK=
LN-405	NYX0d2hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWWyNXhzUUN3ME20PE4xQDJ5IN88US=>	NHjnc2xUSU6JRWK=
NCI-H727	M4LIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnRTWM2OD12OD63O\|I3KM7:TR?=	M2j0U3NCVkeHUh?=
D-502MG	MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PiU2lEPTB;NEiuPVY4PiEQvF2=	M1;WenNCVkeHUh?=
GMS-10	NYHLOWpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTR7LkK5O\|Qh\|ryP	M3jDPXNCVkeHUh?=
MEL-JUSO	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rRNmlEPTB;NEmuN\|Q4KM7:TR?=	M2iwTHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-MEK / MEK / p-ERK / ERK / p-FAK(S910); PubMed: 23076151 J Biol Chem WM793 and WM793-Res NRAS cells were seeded overnight in the absence of PLX4720 and then treated with 1 μm PLX4720 for times ranging from 0 to 24 h. Samples were analyzed by Western blotting for phospho-MEK, total MEK, phospho-ERK1/2, total ERK1/2, phospho-S910 FAK, and total FAK. p-EGFR 1173 / EGFR / p-Akt / Akt; PubMed: 26023796 Oncotarget Three BRAF(V600E) glioma cell lines, NMC-G1, AM38 and DBTRG-05MG were subjected to a 24 hour time course treatment with 5 μM PLX4720 in the presence or absence of 1 μM HKI-272. These cells were serum starved for 16 hours before being stimulated with 10% FBS and harvested for immunoblotting analysis. Cells treated with PLX4720 alone showed an initial suppression of MEK and ERK phosphorylation followed by a profound rebound of MAPK pathway activation as early as one hour post-PLX4720 treatment. Elevated levels of EGFR phosphorylation were also observed in the PLX4720 treated cells. The extent of Akt phosphorylation increased upon PLX4720 treatment, although the extent varies between cell lines. In contrast, no reactivation of EGFR, MEK, ERK or Akt was observed in cells pre-treated with HKI-272. p27 / Cyclin D1 / pRb; PubMed: 21828154 Invest Ophthalmol Vis Sci Immunoblot analysis revealed that PLX4720 (3 μM) decreased levels of phosphorylated ERK, decreased levels of cyclin D1, increased levels of p27, and decreased levels of phosphorylated Rb in BRAF-mutant (OCM3) cells. On the contrary, in Gα-mutant (OMM1.3) UM cells, PLX4720 induced a paradoxical increase in phosphorylated ERK and Rb levels and an early increase in cyclin D1 levels but did not stimulate p27 levels. pAkt(Ser473) / pAkt(Thr308); PubMed: 21828154 Invest Ophthalmol Vis Sci Immunoblot analysis revealed that both AZD6244 and PLX4720 induced an early (within 2–6 hours of exposure) increase in the levels of phosphorylated Akt (at residues Ser473 and Thr308) in both BRAF-mutant OCM3 and Gα-mutant OMM1.3 cells. Eventually, and with prolonged drug exposure, the phosphorylation of Akt returned to baseline in Gα-mutant OMM1.3 cells and decreased even below baseline levels in BRAF-mutant OCM3 cells.	23076151 26023796 21828154
Immunofluorescence	LAMP1; PubMed: 30979895 Nat Commun Representative images of LysoTracker Red (red) and LAMP1 (green) immunostaining of PLX4720 (1 μM, 12 h-treated) A375 cells with depletion of the indicated genes. Note the reduced lysosome staining in PLX4720-treated cells upon TFEB depletion. ZKSCAN3 / TFEB ; PubMed: 30979895 Nat Commun Representative confocal images of subcellular translocation of endogenous TFEB (green) and ZKSCAN3 (red) in A375 cells treated with PLX4720 (1 μM, 12 h). n = 3 independent experiments.	30979895
Growth inhibition assay	Cell viability; PubMed: 27848137 J Neurooncol AM-38 and DBTRG-05MG cells were treated for 5 days. Media was changed once every 3 days. Cell viability was measured using WST-1 assay. Error bars indicate the variation between triplicate measurements. PLX4720 and PD0325901 alone or in combination reduced cell viability significantly. However, combined therapy led to the most significant cell viability reduction compared to either monotherapy in both AM-38 and DBTRG-05MG cell lines.	27848137
ELISA	mIFN-γ; PubMed: 23204132 Clin Cancer Res (C, D and E) IFN-γ secretion by pmel-1 T cells co-cultured with transduced melanoma cells (after cell sorting) that had been pre-treated with the indicated concentrations of PLX4720, as determined by ELISA. (P<0.05, * P<0.01) Data are representative of 3 independent experiments.	23204132

In vivo

Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-Raf^V600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-Raf^V600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. ^[1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. ^[3]

Protocol

Kinase Assay:^[1]	- Collapse In vitro Raf kinase activities: The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl₂, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:^[1]	- Collapse Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells Concentrations: Dissolved in DMSO, final concentrations ~1 mM Incubation Time: 24, 48, and 72 hours Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells Dosages: 5, 20, or 100 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+50% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PLX-4720 SDF

Molecular Weight	413.83
Formula	C₁₇H₁₄ClF₂N₃O₃S
CAS No.	918505-84-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What would you recommend to make working solution for intraperitoneal injection into mice?
Answer:
PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. LY03009120 induces autophagy. Phase 1.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Dabrafenib (GSK2118436)

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.
Sorafenib

Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Sorafenib Tosylate

Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. GW5074 inhibits LK-induced apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

PLX-4720